Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 18/20 | 0.40 |
| ▸ | FLT1 | P17948 | 1/20 | 0.39 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.39 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24332597 | 0.86 | FLT1 (0.43) | MAPK14FLT1MAPK11MINK1KDM4E | |
| SCHEMBL983534 | 0.85 | FLT1 (0.39) | MAPK14FLT1MAPK11MINK1KDM4E | |
| SCHEMBL15028544 | 0.80 | MAPK14 (0.38) | MAPK14 | |
| SCHEMBL15007237 | 0.73 | HSD11B1 (0.52) | MAPK14KDM4E | |
| SCHEMBL10364834 | 0.72 | PDE5A (0.39) | MAPK14FLT1MAPK11MINK1KDM4E | |
| SCHEMBL10364829 | 0.71 | FLT1 (0.46) | MAPK14FLT1MAPK11MINK1 | |
| SCHEMBL15086681 | 0.70 | PIM1 (0.36) | MAPK14FLT1MAPK11MINK1KDM4E | |
| SCHEMBL15086682 | 0.69 | FLT1 (0.42) | MAPK14FLT1MAPK11MINK1 | |
| SCHEMBL8772078 | 0.69 | S100A4 (0.61) | KDM4E | |
| SCHEMBL15007181 | 0.69 | MAPK14 (0.60) | MAPK14FLT1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2788345-B1 | DERIVATIVES OF 4-HYDROXY-1,2,3,4-TETRAHYDRONAPHTALEN-1-YL UREA AND THEIR USE IN THE TREATMENT OF, INTER ALIA, DISEASES OF THE RESPIRATORY TRACT | CHIESI FARM SPA (IT) | 2020-06-10 | — | — | EP | disclosed |
| EP-2788345-B1 | DERIVATIVES OF 4-HYDROXY-1,2,3,4-TETRAHYDRONAPHTALEN-1-YL UREA AND THEIR USE IN THE TREATMENT OF, INTER ALIA, DISEASES OF THE RESPIRATORY TRACT | CHIESI FARM SPA (IT) | 2020-06-10 | — | — | EP | disclosed |
| US-9458154-B2 | Kinase inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2016-10-04 | — | — | US | disclosed |
| US-9458154-B2 | Kinase inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2016-10-04 | — | — | US | disclosed |
| US-9458154-B2 | Kinase inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2016-10-04 | — | — | US | disclosed |
| US-20150057273-A1 | KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2015-02-26 | — | — | US | disclosed |
| US-20150057273-A1 | KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2015-02-26 | — | — | US | disclosed |
| US-20150057273-A1 | KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2015-02-26 | — | — | US | disclosed |
| EP-2580212-B1 | Urea derivatives and their therapeutic use in the treatment of, inter alia, diseases of the respiratory tract | CHIESI FARMA SPA (IT) | 2015-01-28 | — | — | EP | disclosed |
| US-8916708-B2 | Urea derivatives and their therapeutic use in the treatment of, inter alia, diseases of the respiratory tract | CHIESI FARMACEUTICI S.P.A. (IT) | 2014-12-23 | — | — | US | disclosed |
| EP-2788345-A1 | DERIVATIVES OF 4-HYDROXY-1,2,3,4-TETRAHYDRONAPHTALEN-1-YL UREA AND THEIR USE IN THE TREATMENT OF, INTER ALIA, DISEASES OF THE RESPIRATORY TRACT | Chiesi Farmaceutici S.p.A. (IT) | 2014-10-15 | — | — | EP | disclosed |
| WO-2013083206-A1 | DERIVATIVES OF 4-HYDROXY-1,2,3,4-TETRAHYDRONAPHTALEN-1-YL UREA AND THEIR USE IN THE TREATMENT OF, INTER ALIA, DISEASES OF THE RESPIRATORY TRACT | CHIESI FARMACEUTICI S.P.A. (IT) | 2013-06-13 | — | — | WO | disclosed |
| WO-2013083206-A1 | DERIVATIVES OF 4-HYDROXY-1,2,3,4-TETRAHYDRONAPHTALEN-1-YL UREA AND THEIR USE IN THE TREATMENT OF, INTER ALIA, DISEASES OF THE RESPIRATORY TRACT | CHIESI FARMACEUTICI S.P.A. (IT) | 2013-06-13 | — | — | WO | disclosed |
| US-20130143914-A1 | UREA DERIVATIVES AND THEIR THERAPEUTIC USE IN THE TREATMENT OF, INTER ALIA, DISEASES OF THE RESPIRATORY TRACT | CHIESI FARMACEUTICI S.P.A. (IT) | 2013-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130143914-A1 | UREA DERIVATIVES AND THEIR THERAPEUTIC USE IN THE TREATMENT OF, INTER ALIA, DISEASES OF THE RESPIRATORY TRACT | ARG2, MAPK1, URB2 | MAPK14 40/4885FLT1 2645/4885MAPK11 96/4885 |
| US-20150057273-A1 | KINASE INHIBITORS | MAPK1, MAP3K1, MAPK4 | MAPK14 27/4885FLT1 3051/4885MAPK11 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.